In a report issued yesterday, William Blair analyst Amanda Murphy maintained a Market Perform rating on Bio-Reference Laboratories (NASDAQ:BRLI), after reporting third quarter 2014 …
In a research report issued today, William Blair analyst Amanda Murphy reiterated an Outperform rating on Myriad Genetics (MYGN), following the company’s fiscal fourth quarter results that were slightly better-than-expected. No …
After the markets closed on Thursday, July 24, Pacific Biosciences (PACB) reported second-quarter results that were in line with expectations, though the company’s …
In a research report issued yesterday, William Blair analyst Amanda Murphy reiterated an Outperform rating on Illumina (ILMN), with a $200 fair value. The call comes following a survey that shows …
In reaction to NeoGenomics (NEO) second-quarter earnings release, William Blair analyst Amanda Murphy maintained an Outperform rating, following 2Q14 report. No price target …
